83486
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 8
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.393311058
- umap2_2d
- 1.657163364
- umap1_3d
- 0.2070994
- umap2_3d
- 1.931776194
- umap3_3d
- -2.038957901
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.440
- G2M_CHECKPOINT+0.380
- HEDGEHOG_SIGNALING+0.260
- INTERFERON_ALPHA_RESPONSE+0.250
- SPERMATOGENESIS+0.240
- NOTCH_SIGNALING+0.210
- WNT_BETA_CATENIN_SIGNALING+0.140
- APICAL_SURFACE+0.080
- MYC_TARGETS_V1+0.070
- KRAS_SIGNALING_DN+0.060
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.550
- P53_PATHWAY-0.380
- TNFA_SIGNALING_VIA_NFKB-0.380
- APOPTOSIS-0.310
- PEROXISOME-0.300
- OXIDATIVE_PHOSPHORYLATION-0.290
- HYPOXIA-0.280
- PROTEIN_SECRETION-0.250
- TGF_BETA_SIGNALING-0.240
- KRAS_SIGNALING_UP-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG357 | — | — | 0.822 |
| 2 | SRR6013553 | — | cohortA3 | 0.817 |
| 3 | BS_3MS8WVNR | high-grade glioma | — | 0.770 |
| 4 | BS_N5DVEJXT | EPN | Supratentorial EPN | 0.760 |
| 5 | X3bde0089.a1cb.45b8.879b.4408eaa25707 | — | cohortMD1 | 0.755 |
| 6 | SRR8613722 | — | E | 0.751 |
| 7 | TCGA-50-5946-01A-11R-1755-07 | — | cohortA1 | 0.746 |
| 8 | BSR_21_0015_A1_S76 | — | B | 0.743 |
| 9 | 02c0aa6a-a7ea-4606-8449-7437df54802c | — | — | 0.741 |
| 10 | MNG1288 | — | — | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |